-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Critical Analysis: Fresh Tracks Therapeutics (FRTX) and The Competition
Critical Analysis: Fresh Tracks Therapeutics (FRTX) and The Competition
Fresh Tracks Therapeutics (NASDAQ:FRTX – Get Rating) is one of 277 publicly-traded companies in the "Biological products, except diagnostic" industry, but how does it compare to its rivals? We will compare Fresh Tracks Therapeutics to similar companies based on the strength of its risk, analyst recommendations, institutional ownership, dividends, earnings, profitability and valuation.
Profitability
This table compares Fresh Tracks Therapeutics and its rivals' net margins, return on equity and return on assets.
Get Fresh Tracks Therapeutics alerts:| Net Margins | Return on Equity | Return on Assets | |
| Fresh Tracks Therapeutics | -453.11% | -133.55% | -108.52% |
| Fresh Tracks Therapeutics Competitors | -4,576.34% | -104.23% | -37.17% |
Risk and Volatility
Fresh Tracks Therapeutics has a beta of 0.29, suggesting that its share price is 71% less volatile than the S&P 500. Comparatively, Fresh Tracks Therapeutics' rivals have a beta of 0.75, suggesting that their average share price is 25% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Fresh Tracks Therapeutics and its rivals, as reported by MarketBeat.com.| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fresh Tracks Therapeutics | 0 | 0 | 0 | 0 | N/A |
| Fresh Tracks Therapeutics Competitors | 895 | 3857 | 10720 | 160 | 2.65 |
Fresh Tracks Therapeutics currently has a consensus price target of $4.00, suggesting a potential upside of 61.29%. As a group, "Biological products, except diagnostic" companies have a potential upside of 70.07%. Given Fresh Tracks Therapeutics' rivals higher probable upside, analysts plainly believe Fresh Tracks Therapeutics has less favorable growth aspects than its rivals.
Earnings & Valuation
This table compares Fresh Tracks Therapeutics and its rivals top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Fresh Tracks Therapeutics | $400,000.00 | -$39.47 million | -0.30 |
| Fresh Tracks Therapeutics Competitors | $767.19 million | $146.84 million | -2.01 |
Fresh Tracks Therapeutics' rivals have higher revenue and earnings than Fresh Tracks Therapeutics. Fresh Tracks Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Insider and Institutional Ownership
7.7% of Fresh Tracks Therapeutics shares are owned by institutional investors. Comparatively, 46.5% of shares of all "Biological products, except diagnostic" companies are owned by institutional investors. 4.5% of Fresh Tracks Therapeutics shares are owned by company insiders. Comparatively, 16.3% of shares of all "Biological products, except diagnostic" companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Fresh Tracks Therapeutics rivals beat Fresh Tracks Therapeutics on 8 of the 10 factors compared.
About Fresh Tracks Therapeutics
(Get Rating)
Fresh Tracks Therapeutics, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. Its pipeline consists of new molecular entities targeting the treatment of the following indications: hyperhidrosis, allergic contact dermatitis, androgenic alopecia, cutaneous t-cell lymphoma and psoriasis. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in 2009 and is headquartered in Boulder, CO.
Receive News & Ratings for Fresh Tracks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresh Tracks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Fresh Tracks Therapeutics (NASDAQ:FRTX – Get Rating) is one of 277 publicly-traded companies in the "Biological products, except diagnostic" industry, but how does it compare to its rivals? We will compare Fresh Tracks Therapeutics to similar companies based on the strength of its risk, analyst recommendations, institutional ownership, dividends, earnings, profitability and valuation.
Fresh Tracks Therapeutics（纳斯达克股票代码：FRTX — Get Ratings）是 “生物制品，诊断除外” 行业的277家上市公司之一，但与竞争对手相比如何？我们将根据风险实力、分析师建议、机构所有权、股息、收益、盈利能力和估值，将Fresh Tracks Therapeutics与同类公司进行比较。
Profitability
盈利能力
This table compares Fresh Tracks Therapeutics and its rivals' net margins, return on equity and return on assets.
该表比较了Fresh Tracks Therapeutics及其竞争对手的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Fresh Tracks Therapeutics | -453.11% | -133.55% | -108.52% |
| Fresh Tracks Therapeutics Competitors | -4,576.34% | -104.23% | -37.17% |
| 净利润 | 股本回报率 | 资产回报率 | |
| Fresh Tracks | -453.11% | -133.55% | -108.52% |
| Fresh Tracks 疗法 | -4,576.34% | -104.23% | -37.17% |
Risk and Volatility
风险和波动性
Fresh Tracks Therapeutics has a beta of 0.29, suggesting that its share price is 71% less volatile than the S&P 500. Comparatively, Fresh Tracks Therapeutics' rivals have a beta of 0.75, suggesting that their average share price is 25% less volatile than the S&P 500.
Fresh Tracks Therapeutics的beta值为0.29，这表明其股价的波动性比标准普尔500指数低71％。相比之下，Fresh Tracks Therapeutics的竞争对手的beta值为0.75，这表明他们的平均股价波动性比标准普尔500指数低25％。
Analyst Recommendations
分析师建议
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fresh Tracks Therapeutics | 0 | 0 | 0 | 0 | N/A |
| Fresh Tracks Therapeutics Competitors | 895 | 3857 | 10720 | 160 | 2.65 |
| 卖出评级 | 保持收视率 | 买入评级 | 强劲的买入评级 | 评分分数 | |
| Fresh Tracks | 0 | 0 | 0 | 0 | 不适用 |
| Fresh Tracks 疗法 | 895 | 3857 | 10720 | 160 | 2.65 |
Fresh Tracks Therapeutics currently has a consensus price target of $4.00, suggesting a potential upside of 61.29%. As a group, "Biological products, except diagnostic" companies have a potential upside of 70.07%. Given Fresh Tracks Therapeutics' rivals higher probable upside, analysts plainly believe Fresh Tracks Therapeutics has less favorable growth aspects than its rivals.
Fresh Tracks Therapeutics目前的共识目标价为4.00美元，这表明潜在的上涨空间为61.29％。作为一个整体，“生物制品，诊断除外” 公司的潜在上涨空间为70.07％。鉴于Fresh Tracks Therapeutics的竞争对手可能更高的上行空间，分析师显然认为Fresh Tracks Therapeutics的增长方面不如竞争对
Earnings & Valuation
收益与估值
This table compares Fresh Tracks Therapeutics and its rivals top-line revenue, earnings per share and valuation.
该表比较了Fresh Tracks Therapeutics及其竞争对手的营收收入、每股收益和估值。
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Fresh Tracks Therapeutics | $400,000.00 | -$39.47 million | -0.30 |
| Fresh Tracks Therapeutics Competitors | $767.19 million | $146.84 million | -2.01 |
| 总收入 | 净收入 | 市盈率 | |
| Fresh Tracks | 400,000.00 美元 | -3,947 万美元 | -0.30 |
| Fresh Tracks 疗法 | 7.6719 亿美元 | 1.4684 亿美元 | -2.01 |
Fresh Tracks Therapeutics' rivals have higher revenue and earnings than Fresh Tracks Therapeutics. Fresh Tracks Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Fresh Tracks Therapeutics的竞争对手的收入和收益比Fresh TrackFresh Tracks Therapeutics的交易市盈率高于竞争对手，这表明它目前比该行业的其他公司更昂贵。
Insider and Institutional Ownership
内部所有权和机构所有权
7.7% of Fresh Tracks Therapeutics shares are owned by institutional investors. Comparatively, 46.5% of shares of all "Biological products, except diagnostic" companies are owned by institutional investors. 4.5% of Fresh Tracks Therapeutics shares are owned by company insiders. Comparatively, 16.3% of shares of all "Biological products, except diagnostic" companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Fresh Tracks Therapeutics7.7％的股份由机构投资者持有。相比之下，所有 “生物制品，诊断除外” 公司的46.5％的股份由机构投资者持有。Fresh Tracks Therapeutics的4.5％股份由公司内部人士持有。相比之下，所有 “生物制品，诊断除外” 公司的16.3％的股份由公司内部人士持有。强大的机构所有权表明，大型基金经理、对冲基金和捐赠基金认为一家公司已为长期增长做好了准备。
Summary
摘要
Fresh Tracks Therapeutics rivals beat Fresh Tracks Therapeutics on 8 of the 10 factors compared.
在比较的10个因素中，Fresh Tracks Therapeutics的竞争对手在8个因素上击败
About Fresh Tracks Therapeutics
关于 Fresh Tracks 治疗
(Get Rating)
（获取评分）
Fresh Tracks Therapeutics, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. Its pipeline consists of new molecular entities targeting the treatment of the following indications: hyperhidrosis, allergic contact dermatitis, androgenic alopecia, cutaneous t-cell lymphoma and psoriasis. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in 2009 and is headquartered in Boulder, CO.
Fresh Tracks Therapeutics, Inc. 参与开发治疗皮肤病的处方疗法。其产品线由针对以下适应症治疗的新分子实体组成：多汗症、过敏性接触性皮炎、雄激素性脱发、皮肤t细胞淋巴瘤和牛皮癣。该公司由 Reginald L. Hardy 和 Andrew D. Sklawer 于 2009 年创立，总部位于科罗拉多州博尔德。
Receive News & Ratings for Fresh Tracks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresh Tracks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
每天接收 Fresh Tracks Therapeutics -在下面输入您的电子邮件地址，通过Marketbeat.com的免费每日电子邮件时事通讯接收Fresh Tracks Therapeutics及相关公司的最新新闻和分析师评级的简明每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧